Clinical Trials

10 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03213977 2024-03-27

R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL

475 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06033820 2024-03-13

Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

20 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06290817 2024-03-04

Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI

62 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03650933 2024-02-20

A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients

360 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06224309 2024-02-09

Preliminary Assessment of [18F]BL40 in PET/CT Scans

LymphoidOther hematologic neoplasmPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05875428 2024-02-08

Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

104 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05234684 2024-02-07

BELIEVE-01

150 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04263584 2024-01-05

COPA-R-CHOP

62 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06164327 2023-12-11

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Unknown

75 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04089215 2023-11-24

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

82 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04870853 2023-11-14

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

150 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03121456 2023-11-13

LYMPHODTECT

74 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05290090 2023-10-17

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

31 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06074107 2023-10-11

Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects

128 enrolled

Phase EARLY_PHASE1 Unknown

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05673447 2023-08-28

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

12 enrolled

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05871684 2023-08-01

A Combination Study of CAR-T Therapy in r/r B-NHL

48 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05887726 2023-07-27

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Lymphoma, Large B-Cell, Diffuse

NCT05020392 2023-07-25

Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma

24 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02825836 2023-07-13

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Phase 1/2 Unknown

130 enrolled

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05940051 2023-07-11

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

35 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05940064 2023-07-11

Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

DermatologicLymphoidOther hematologic neoplasmThoracic

Lymphoma, Large B-Cell, Diffuse

NCT04763083 2023-07-07

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Phase 1 Unknown

90 enrolled

Carcinoma, Non-Small-Cell Lung, Lymphoma, Follicular, Melanoma, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05715606 2023-07-05

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Phase EARLY_PHASE1 Unknown

18 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05923879 2023-06-28

Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

NCT05907447 2023-06-18

A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types

10,000 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell

NCT05883709 2023-06-01

A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL

15 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05179733 2023-05-23

The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years

280 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05863845 2023-05-18

Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

52 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05816746 2023-05-09

Decitabine and Anti-PD-1 in R/R DLBCL

20 enrolled

Extranodal Extension, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05823701 2023-04-21

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

23 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04271410 2023-04-18

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Phase 1/2 Unknown

80 enrolled

Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05786989 2023-03-28

Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma

Phase 4 Unknown

32 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05784987 2023-03-27

R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

60 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05777369 2023-03-21

R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

NCT05728632 2023-02-23

CONTROL

80 enrolled

BreastLymphoid

Breast Neoplasms, Lymphoma, Large B-Cell, Diffuse, Ventricular Dysfunction, Left, Cardiotoxicity

NCT03797170 2023-02-08

Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma

50 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04113226 2023-02-08

Relyage

114 enrolled

LymphoidSarcoma

Recurrence, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT04381741 2023-02-06

CICPD

Phase 1 Unknown

24 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05498259 2023-02-03

Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

46 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02752815 2022-12-05

Reduced Chemotherapy in Low Risk DLBCL

Phase 4 Unknown

290 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05575973 2022-10-12

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

55 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05532761 2022-09-08

QUALITOP CAR-T

Lymphoma, Large B-Cell, Diffuse

NCT05189782 2022-08-31

Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma

15 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01357733 2022-08-05

Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients

53 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04502394 2022-08-04

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Phase 1/2 Unknown

84 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05466318 2022-07-25

ChiCGB vs BEAM in High-risk or R/R Lymphomas

306 enrolled

Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03736616 2022-07-22

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

47 enrolled

Phase EARLY_PHASE1 Unknown

Lymphoma, Large B-Cell, Diffuse

NCT05444322 2022-07-11

A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

18 enrolled